Loading...
Vernalis Research2019-03-22T05:39:19+00:00

Welcome to Vernalis Research

We develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.

Our approach

Our established group of experienced scientists is based at our fully-equipped research laboratories in Cambridge, UK.

We integrate fragment-based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets.

We have the experience and capabilities for progressing projects from target identification through to clinical candidate. We have generated lead compounds on enzymes, protein-protein interactions and GPCRs, leading to an average of one pre-clinical candidate per year, with disclosed programs for inhibitors of Chk1, Hsp90, Bcl-2, Mcl-1, FAAH and A2A.

Our business model

We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical companies and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Current disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck and Asahi Kasei Pharma, and we seek additional partnerships.

We also have an extensive portfolio of partnered and unpartnered drug candidates in pre-clinical and clinical development. To find out more, please contact us.

Latest news

Successes in Daiichi Sankyo Collaboration

November 13th, 2018|

CAMBRIDGE, England (November 13, 2018) – Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that began [...]

Ligand anounces the close of its acquisition of Vernalis

October 10th, 2018|

Ligand’s portfolio now includes more than 178 shots on goal SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its acquisition of Vernalis plc has successfully closed and Vernalis will now operate as [...]

Next event

Fragments 2019

March 24, 2019 - March 26, 2019

Contributor: Rod Hubbard

Current partnerships

This website uses cookies and third party services. Read our Privacy Policy Ok